Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Amortization of Deferred Charges (2022 - 2025)

Historic Amortization of Deferred Charges for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to $1.2 million.

  • Phathom Pharmaceuticals' Amortization of Deferred Charges rose 1592.92% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 2503.45%. This contributed to the annual value of $3.8 million for FY2024, which is 535.86% up from last year.
  • Latest data reveals that Phathom Pharmaceuticals reported Amortization of Deferred Charges of $1.2 million as of Q3 2025, which was up 1592.92% from $1.2 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $1.2 million during Q3 2025, with a 5-year trough of $806000.0 in Q1 2024.
  • Moreover, its 4-year median value for Amortization of Deferred Charges was $899000.0 (2023), whereas its average is $954733.3.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first crashed by 809.58% in 2024, then surged by 4156.33% in 2025.
  • Phathom Pharmaceuticals' Amortization of Deferred Charges (Quarter) stood at $890000.0 in 2022, then rose by 1.01% to $899000.0 in 2023, then grew by 16.91% to $1.1 million in 2024, then increased by 12.18% to $1.2 million in 2025.
  • Its Amortization of Deferred Charges was $1.2 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.1 million in Q1 2025.